AC Immune SA (NASDAQ:ACIU – Get Free Report) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 509,400 shares, a drop of 9.1% from the March 31st total of 560,600 shares. Based on an average daily volume of 180,700 shares, the days-to-cover ratio is currently 2.8 days. Approximately 0.9% of the company’s shares are short sold.
AC Immune Trading Up 3.3 %
Shares of NASDAQ ACIU opened at $2.48 on Wednesday. The firm’s 50-day moving average is $3.06 and its 200-day moving average is $3.33. AC Immune has a 1 year low of $1.78 and a 1 year high of $5.14. The firm has a market capitalization of $245.27 million, a PE ratio of -3.49 and a beta of 1.00.
AC Immune (NASDAQ:ACIU – Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $16.71 million for the quarter, compared to the consensus estimate of $16.36 million. As a group, equities research analysts anticipate that AC Immune will post -0.78 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of AC Immune in a research note on Friday, March 15th.
Get Our Latest Stock Analysis on ACIU
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also
- Five stocks we like better than AC Immune
- Basic Materials Stocks Investing
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What Are Dividend Challengers?
- Hilton Demonstrates Asset Light is Right for Investors
- How to Invest in Blue Chip Stocks
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.